Outlook Therapeutics, Inc(NASDAQ:OTLK) 
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Ph...
Website: http://www.outlooktherapeutics.com
Founded: 2009
Full Time Employees: 14
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.19
H 1.21
L 1.11
C 1.20
V 372,605
10EMA 1.20
20EMA 1.20
60EMA 1.20
120EMA 1.20
250EMA 1.20